Outcomes of COVID-19 Infection in Patients With and Without Cancer – An Analysis of Data From 14 Hospitals

The American Association for Cancer Research (AACR) Annual Meeting was held virtually / remotely this year, and a study presented in the "COVID-19 and Cancer" session reported that serious COVID-19-related events were more common in cancer patients and that, among cancer patients, those with metastatic disease were at the greatest risk.
Study Details
The study, which covered the period from 1 January to 24 February 2020 at 14 hospitals in Wuhan, China, examined COVID-19 infection in 105 cancer patients. They were compared with a randomly selected control group of 536 people who had COVID-19 infection but did not have cancer. Lung cancer was the most common cancer type, with 22 patients (22%), followed by gastrointestinal (stomach and intestinal system) cancer in 13 patients (12%), breast cancer in 11 patients (10%), thyroid cancer in 11 patients (10%) and hematological cancers in 9 patients (9%).
Key Findings
Compared with COVID-19 patients without a cancer diagnosis, cancer patients had a 2.3-fold higher risk of mortality (death). They also had a 2.8-fold higher risk of admission to the intensive care unit (ICU), a 2.8-fold higher risk of developing at least one severe or critical symptom, and a greater need for invasive mechanical ventilation (being placed on a breathing machine).
Cancer patients had a longer median hospital stay than patients without cancer (27 versus 17.7 days).
Patients with hematological cancers (originating in the blood and bone marrow) had higher rates of death (33%), ICU admission (44%), severe / critical symptoms (67%) and use of invasive mechanical ventilation (22%) than patients with other cancer types. After hematological cancers, patients with lung cancer appeared to have the second-highest risk levels for these outcomes (18%, 27%, 50% and 18%, respectively).
In patients with metastatic cancer, the risk of COVID-19-related death was increased 5.5-fold, ICU admission 6.6-fold, and severe conditions 5.9-fold. No significant difference in these outcomes was observed between patients with non-metastatic cancer and those without cancer.
Death, ICU admission, critical symptoms and use of invasive mechanical ventilation were significantly more common in patients with lung cancer or lung metastases than in other cancer patients without lung metastases.
Among cancer patients who contracted COVID-19 infection, the treatments received 40 days before symptom onset were as follows: 13 received radiotherapy; 17 chemotherapy; 8 surgery; 4 targeted therapy; and 6 immunotherapy. All patients who received targeted therapy or immunotherapy had a diagnosis of lung cancer. Of the six patients who received immunotherapy, two died and four had critical symptoms.
Having undergone surgery was found to pose a high risk of poor COVID-19-related outcomes; among the surgical patients, two died, three were admitted to intensive care, five had severe / serious symptoms and two required invasive ventilation. Radiotherapy was not associated with an increased risk of adverse outcomes.
Conclusion
The findings of this study show that cancer patients infected with SARS-CoV-2 tend to have more serious outcomes than patients without cancer. In addition, patients with hematological cancer, lung cancer and metastatic-stage cancer had higher rates of severe events than other cancer patients. Furthermore, patients who had undergone cancer surgery tended to have higher mortality rates and more critical symptoms. These results support our policy of rigorously protecting cancer patients and the healthcare workers who care for them.
Sources
AACR 2020: Outcomes of COVID-19 Infection in Patients With vs Without Cancer: Analysis From 14 Hospitals.
ascopost.com - 29 April 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.